Gayatri BioOrganics Limited has issued a formal clarification to BSE Limited regarding recent movement in its share price, confirming that no price-sensitive events or extraordinary developments have occurred within the company that would account for the price fluctuation.

Regulatory Response to Exchange Inquiry

The clarification came in response to BSE's inquiry dated March 13, 2026, regarding the movement in the company's share price. In its response dated March 14, 2026, the company explicitly stated that there are no events, information, or developments that have a bearing on the operation or performance of the company, including any price-sensitive information that may result in the increase in share price.

Company's Position on Price Movement

The company emphasized that no extraordinary events have taken place that would cause a rise in its share price. This clarification aligns with the requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to disclose material events and information that could impact share prices.

Commitment to Future Disclosures

Gayatri BioOrganics assured the exchange that any material events arising in the future will be promptly communicated to BSE without fail. The clarification was digitally signed by Whole time Director Sreedhara Reddy Kanaparthy on March 14, 2026, demonstrating the company's commitment to maintaining transparency and regulatory compliance.

The company, headquartered in Hyderabad, Telangana, continues to maintain its obligations under SEBI regulations while ensuring proper communication with stock exchanges regarding any developments that may impact investor interests.

Gayatri Bioorganics Limited has announced its unaudited financial results for the third quarter of fiscal year 2026, ended December 31, 2025. The company reported a net loss of ₹21.71 lakhs for the quarter, representing a significant increase from the ₹16.06 lakhs loss recorded in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance showed deterioration across key metrics. With no revenue from operations reported during the quarter, the entire loss stemmed from operational expenses totaling ₹21.71 lakhs.

Expense Breakdown

The company's expenses for Q3 FY26 were distributed across three main categories. Employee benefits expenses stood at ₹2.55 lakhs, up from ₹2.14 lakhs in the previous year quarter. Finance costs increased to ₹9.44 lakhs from ₹7.53 lakhs, while other expenses rose to ₹9.72 lakhs compared to ₹6.39 lakhs in Q3 FY25.

Nine-Month Performance

For the nine-month period from April 1, 2025, to December 31, 2025, Gayatri Bioorganics reported a cumulative net loss of ₹69.13 lakhs, substantially higher than the ₹55.19 lakhs loss in the corresponding period of the previous year.

Regulatory Compliance and Publication

Pursuant to SEBI Regulation 47, Gayatri BioOrganics Limited published its unaudited financial results in newspapers on February 11, 2026. The company published the results in Financial Express (English newspaper) and Nava Telangana (Telugu newspaper), providing investors with QR code access to complete financial results on the company's webpage.

Corporate Governance and Board Approval

The Board of Directors, in their meeting held on February 10, 2026, at 11:30 AM at the company's registered office, considered and approved the unaudited financial results. The meeting concluded at 12:25 PM. The results were reviewed by the Audit Committee before being taken on record by the Board. The company has filed the outcome of the board meeting with BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Financial Highlights

The company maintained its paid-up equity share capital at ₹7,878.81 lakhs throughout the reporting period. Basic and diluted earnings per share stood at ₹(0.03) for the quarter, compared to ₹(0.02) in the corresponding previous quarter. No exceptional items were reported during the quarter, and the company operates as a single segment business.

The financial statements have been prepared on a going concern basis, supported by a comfort letter from the company's promoters regarding future business continuity. The results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. MGR & CO, Chartered Accountants, conducted the limited review of the unaudited financial results.